12.69
0.05 (0.40%)
| Penutupan Terdahulu | 12.64 |
| Buka | 12.64 |
| Jumlah Dagangan | 1,694,691 |
| Purata Dagangan (3B) | 2,320,288 |
| Modal Pasaran | 1,641,931,136 |
| Harga / Pendapatan (P/E Ke hadapan) | 222.22 |
| Harga / Jualan (P/S) | 1.68 |
| Harga / Buku (P/B) | 1.48 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 28 Oct 2025 |
| Margin Keuntungan | -11.54% |
| Margin Operasi (TTM) | -16.56% |
| EPS Cair (TTM) | -0.610 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | 7.50% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 68.08% |
| Nisbah Semasa (MRQ) | 2.05 |
| Aliran Tunai Operasi (OCF TTM) | 7.61 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -2.21 M |
| Pulangan Atas Aset (ROA TTM) | -2.75% |
| Pulangan Atas Ekuiti (ROE TTM) | -8.56% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Diagnostics & Research (US) | Bercampur | Menaik |
| Diagnostics & Research (Global) | Bercampur | Menaik | |
| Stok | NeoGenomics, Inc. | Menaik | Menurun |
AISkor Stockmoo
| Konsensus Penganalisis | 3.0 |
| Aktiviti Orang Dalam | -4.0 |
| Volatiliti Harga | -4.5 |
| Purata Bergerak Teknikal | 5.0 |
| Osilator Teknikal | -0.5 |
| Purata | -0.20 |
|
NeoGenomics Inc provides oncology diagnostic testing and consultative services which include technical laboratory services and professional interpretation of laboratory test results by licensed physicians or molecular experts in pathology and oncology. It operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. The company operates in a single segment and derives revenue from clients by providing clinical cancer testing, interpretation, and consultative services, molecular and NGS testing, comprehensive technical and professional services offerings, clinical trials and research, validation laboratory services, and oncology data solutions. |
|
| Sektor | Healthcare |
| Industri | Diagnostics & Research |
| Gaya Pelaburan | Small Growth |
| % Dimiliki oleh Orang Dalam | 1.19% |
| % Dimiliki oleh Institusi | 98.21% |
| Julat 52 Minggu | ||
| Julat Harga Sasaran | ||
| Tinggi | 15.00 (Needham, 18.20%) | Beli |
| Median | 14.00 (10.32%) | |
| Rendah | 13.00 (Piper Sandler, 2.44%) | Beli |
| Purata | 14.00 (10.32%) | |
| Jumlah | 2 Beli | |
| Harga Purata @ Panggilan | 10.55 | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| Piper Sandler | 24 Feb 2026 | 13.00 (2.44%) | Beli | 9.65 |
| Needham | 17 Feb 2026 | 15.00 (18.20%) | Beli | 11.44 |
| 12 Jan 2026 | 14.00 (10.32%) | Beli | 12.49 |
Tiada data dalam julat masa ini.
| Tarikh | Jenis | Butiran |
|---|---|---|
| 27 Jan 2026 | Pengumuman | NeoGenomics to Report Fourth Quarter and Full Year 2025 Financial Results on February 17, 2026 |
| 12 Jan 2026 | Pengumuman | NeoGenomics Announces Preliminary Fourth Quarter and Full-Year 2025 Revenue |
| 05 Jan 2026 | Pengumuman | NeoGenomics to Participate in the 44th Annual J.P. Morgan Healthcare Conference |
| 30 Dec 2025 | Pengumuman | NeoGenomics Appoints Diagnostics and Lab Services Industry Veteran John P. “Jack” Kenny to its Board of Directors |
| 15 Dec 2025 | Pengumuman | NeoGenomics Announces that Natera Has Voluntarily Withdrawn its Appeal in Ongoing RaDaR Patent Litigation |
| 10 Dec 2025 | Pengumuman | NeoGenomics to Present New ctDNA Research at SABCS 2025 |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |